Cosmos Health targets $22.7M US revenue from 18 Series

Cosmos Health Inc. has projected over $22.7 million in annualized U.S. revenue and approximately $17.0 million in implied gross profit from its 18 Series nutraceutical platform, operating at ~75% gross margins. The company, listed on NASDAQ under the symbol COSM, disclosed these targets for four of its five launched products, highlighting early demand and commercial traction in the U.S. market.

The 18 Series is a science-driven platform built on proprietary ingredients, published clinical research, and exact clinical dosing. Since its U.S. launch, Cosmos Health has introduced five products: Noor18™, Liv18™, Cur18™, Fort18™, and Oliv18™. The company expects the platform to become a significant pillar of long-term revenue and a meaningful contributor to profitability.

Financial Projections

The revenue and gross profit figures are based on the company's ~75% gross-margin guidance applied to disclosed revenue projections for four products. The total excludes Oliv18™, which has been launched but does not yet have a disclosed revenue projection.

Product	Category	Projected Annualized U.S. Revenue	Gross Profit¹
Noor18™	Healthy aging / beauty	Over $12.0M	~$9.00M
Liv18™	Liver & metabolic support	Over $5.0M	~$3.75M
Fort18™	Men's wellness	Over $3.2M	~$2.40M
Cur18™	Inflammation & mobility	Over $2.5M	~$1.875M
Total		Over $22.7M	~$17.0M

¹ Gross profit is calculated by applying the Company's approximately 75% gross-margin guidance to its disclosed revenue projections. Total excludes Oliv18™, which is launched but has no disclosed revenue projection.

Strategic Outlook

Cosmos Health is targeting a portfolio of 18 science-based products spanning key health categories. The platform remains at an early stage, and the company expects to provide further updates as additional products are launched and commercial data develops.

Cosmos Health Inc. announced that its wholly-owned subsidiary, Cana Laboratories, has secured new contract manufacturing orders totaling 253,657 units from Nassington and Verisfield. The orders encompass a diverse range of medicines and pharmaceutical products, reinforcing the demand for Cana's manufacturing capabilities and the strength of Cosmos Health's vertically integrated platform.

Order Details

The new contract manufacturing orders include the following products:

Product	Presentation
Gritse oral solution	0.4 mg/ml (bottle x 150 ml)
Gritse forte oral solution	2 mg/ml (bottle x 50 ml)
Gritse forte oral solution	4 mg/ml (bottle x 50 ml)
Fungofort cutaneous spray, solution	30 ml
Paco-4 tablets	250+250+65+35 mg
Dexamethasone	2 mg/5 ml, 50 ml and 150 ml bottle and oral solution presentations
Foproct rectal cream	1 + 1.5%

Strategic Impact

Greg Siokas, CEO of Cosmos Health, stated that these orders reflect the demand for Cana's contract manufacturing capabilities. He emphasized that deepening relationships with established pharmaceutical partners across a broad range of products supports the company's goal of building a diversified manufacturing business. This strategy is aimed at creating long-term value for shareholders.

Company Background

Cosmos Health Inc. is a diversified, vertically integrated global healthcare group incorporated in 2009 in Nevada. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), the company manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes pharmaceuticals and parapharmaceuticals through its subsidiaries in Greece and the UK.